Skip to main content

Table 4 Changes from baseline in COPD symptom scores*

From: One-year treatment with mometasone furoate in chronic obstructive pulmonary disease

  MF-DPI 800 μg QD PM (n = 282) MF-DPI 400 μg BID (n = 283) Placebo (n = 263)
Total COPD symptom scores (daytime)    
   Baseline 2.66 2.78 2.64
   Longitudinal average -0.36 -0.57 -0.11
Total COPD symptom scores (nighttime)    
   Baseline 2.54 2.73 2.65
   Longitudinal average -0.30 -0.50 -0.12
Daytime symptom scores    
Difficulty Breathing    
   Baseline 1.06 1.14 0.99
   Longitudinal average -0.11 -0.23 0.02
Coughing    
   Baseline 0.92 0.91 0.97
   Longitudinal average -0.14 -0.16 -0.10
Wheezing    
   Baseline 0.70 0.74 0.68
   Longitudinal average -0.12 -0.18 -0.04
Nighttime Symptom Scores    
Difficulty breathing    
   Baseline 1.00 1.10 1.01
   Longitudinal average -0.10 -0.18 0.01
Coughing    
   Baseline 0.90 0.91 0.96
   Longitudinal average -0.12 -0.16 -0.08
Wheezing    
   Baseline 0.66 0.73 0.69
   Longitudinal average -0.08 -0.17 -0.05
  1. BID = twice daily; COPD = chronic obstructive pulmonary disease; MF-DPI = mometasone furoate administered via a dry powder inhaler.
  2. A P value of 0.025 was the upper limit of statistical significance based on the modified Bonferroni correction used in this analysis.
  3. *This table shows symptom-score results for subjects in whom baseline and post-baseline diary data were available.
  4. P ≤ 0.003 vs placebo
  5. P < 0.025 vs placebo